Literature DB >> 11592636

Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro.

N Okazaki1, M Narita, S Yamada, K Izumikawa, M Umetsu, T Kenri, Y Sasaki, Y Arakawa, T Sasaki.   

Abstract

Some patients with Mycoplasma pneumoniae infection are clinically resistant to antibiotics such as erythromycin, clarithromycin, or clindamycin. We isolated M. pneumoniae from such patients and found that one of three isolates showed a point mutation in the 23S rRNA gene. Furthermore, 141 EM-sensitive clinical isolates of M. pneumoniae were cultured in broth medium containing 100 microg/ml of erythromycin (EM). Among 11 EM-resistant strains that grew in the medium, point mutations in the 23S rRNA were found in 3 strains at A2063G, 5 strains at A2064G and 3 strains at A2064C. The relationship between the point mutation pattern of these EM-resistant strains and their resistance phenotypes to several macrolide antibiotics was investigated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11592636     DOI: 10.1111/j.1348-0421.2001.tb01293.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  64 in total

1.  Ribosomal mutations in Arcanobacterium pyogenes confer a unique spectrum of macrolide resistance.

Authors:  B Helen Jost; Hien T Trinh; J Glenn Songer; Stephen J Billington
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

2.  In vitro subminimum inhibitory concentrations of macrolide antibiotics induce macrolide resistance in Mycoplasma pneumoniae.

Authors:  G Ou; Y Liu; Y Tang; X You; Y Zeng; J Xiao; L Chen; M Yu; M Wang; C Zhu
Journal:  Hippokratia       Date:  2015 Jan-Mar       Impact factor: 0.471

3.  Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation.

Authors:  Miyuki Morozumi; Keiko Hasegawa; Reiko Kobayashi; Nagako Inoue; Satoshi Iwata; Haruo Kuroki; Naohisa Kawamura; Eiichi Nakayama; Takeshi Tajima; Kouichi Shimizu; Kimiko Ubukata
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

4.  Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae.

Authors:  Tsutomu Yamazaki; Tsuguo Sasaki; Masahiro Takahata
Journal:  Antimicrob Agents Chemother       Date:  2007-03-26       Impact factor: 5.191

5.  Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae.

Authors:  Satowa Suzuki; Tsutomu Yamazaki; Mitsuo Narita; Norio Okazaki; Isao Suzuki; Tomoaki Andoh; Mayumi Matsuoka; Tsuyoshi Kenri; Yoshichika Arakawa; Tsuguo Sasaki
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

6.  Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia.

Authors:  Miyuki Morozumi; Satoshi Iwata; Keiko Hasegawa; Naoko Chiba; Reiko Takayanagi; Keita Matsubara; Eiichi Nakayama; Keisuke Sunakawa; Kimiko Ubukata
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

7.  Mutations in 23S rRNA account for intrinsic resistance to macrolides in Mycoplasma hominis and Mycoplasma fermentans and for acquired resistance to macrolides in M. hominis.

Authors:  S Pereyre; P Gonzalez; B De Barbeyrac; A Darnige; H Renaudin; A Charron; S Raherison; C Bébéar; C M Bébéar
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

Review 8.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

Review 9.  Resistance to Macrolide Antibiotics in Public Health Pathogens.

Authors:  Corey Fyfe; Trudy H Grossman; Kathy Kerstein; Joyce Sutcliffe
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

10.  Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients.

Authors:  Yasuhiro Kawai; Naoyuki Miyashita; Mika Kubo; Hiroto Akaike; Atsushi Kato; Yoko Nishizawa; Aki Saito; Eisuke Kondo; Hideto Teranishi; Satoko Ogita; Takaaki Tanaka; Kozo Kawasaki; Takashi Nakano; Kihei Terada; Kazunobu Ouchi
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.